Otsuka Pharmaceutical
在场
是其中之一......
Otsuka Holdings 是一家在股票代码 4578 (JP) 下上市的公司。
Otsuka Holdings 在 10 个国家有直接业务。Otsuka Holdings 拥有 25家子公司，其中包括 Astex、Astex Pharmaceuticals 和 Cambridge Isotope Laboratories。
他们在：
涉及Otsuka Holdings的并购和融资。
- Otsuka Pharmaceutical has announced the acquisition of Jnana Therapeutics (公布2024八月1号).
高管
查看带有其 166 名主要高管的组织结构图
Otsuka Pharmaceutical 搜索最多的简介
- Makoto Inoue, President and Representative Director
- Hiroshi Sugawara, Board Member
- Susumu Tamai, Vice Chairman of the Board
创建提醒
跟踪 Otsuka Pharmaceutical 的高管变动
药店
Otsuka Holdings 拥有 1,831 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Stemtech and Seacret Direct have announced they will merge (公布2024十二月5号)..
- Recursion Pharma and Exscientia have merged (公布2024十一月27号)..
- Stemtech and Seacret Direct have announced they will merge (公布2024十一月22号)..
药店 行业的其他推荐联系人
消息
Otsuka Pharmaceutical 的最新新闻稿
- Otsuka Pharmaceutical Launches POCARI SWEAT Basketball Dream Project to Promote Sports and International Exchanges｜News Releases | Otsuka Pharmaceutical Co., Ltd.
- Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia｜News Releases | Otsuka Pharmaceutical Co., Ltd.
- Otsuka Obtains Exclusive Global Licensing Rights from Ionis to Ulefnersen, a Potential Treatment for Amyotrophic Lateral Sclerosis Caused by Mutations in the Fused in Sarcoma Gene (FUS-ALS) ｜News Releases | Otsuka Pharmaceutical Co., Ltd.
- Otsuka launches Lupkynis® in Japan｜News Releases | Otsuka Pharmaceutical Co., Ltd.
- Otsuka Provides Update on Sibeprenlimab, an Investigational Monoclonal Antibody for the Treatment of IgA Nephropathy in Adults｜News Releases | Otsuka Pharmaceutical Co., Ltd.
- Otsuka Announces Positive Interim Results from the Phase 3 Trial of Sibeprenlimab for the Treatment of Immunoglobulin A Nephropathy in Adults｜News Releases | Otsuka Pharmaceutical Co., Ltd.
- Otsuka Group Establishes Solar Power Generation Facility in Naka, Tokushima The New Facility Advances the Company’s Carbon Neutrality Initiative | Otsuka Group News | Otsuka Holdings Co., Ltd.searchsearchBack ButtonSearch IconFilter Icon
- Heartful Kawauchi ReceivedJapan Organization for Employment of the Elderly, Persons with Disabilities and Job Seekers President's Award｜News Releases | Otsuka Pharmaceutical Co., Ltd.
- HemeSight®, the First-in-Japan Comprehensive Genomic Profiling Assay for Hematological Malignancies, Receives Its First Regulatory Approval - HemeSight® hematological malignancies gene panel test approved in Japan -｜News Releases | Otsuka Pharmaceutical C
- Otsuka Receives Approval in Japan for Lupkynis® as a Treatment for Lupus Nephritis｜News Releases | Otsuka Pharmaceutical Co., Ltd.
- View more press releases Close
通过电子邮件
